Geno- and phenotypic characteristics and clinical outcomes of CACNA1C gene mutation associated Timothy syndrome, “cardiac only” Timothy syndrome and isolated long QT syndrome 8: A systematic review

János Borbás1, Máté Vámos1, Lidia Hategan1, Lilla Hanák2, Nelli Farkas3, Zsolt Szakács2,4, Dezső Csupor2,5, Bálint Tél6, Péter Kupó1,7, Beáta Csányi1, Viktória Nagy1, András Komócsí7, Tamás Habon4,8, Péter Hegyi2,9,10 and Róbert Sepp1*

1Division of Non-Invasive Cardiology, Department of Internal Medicine, University of Szeged, Member of the European Reference Network for Rare, Low Prevalence, or Complex Diseases of the Heart (ERN GUARD Heart), Szeged, Hungary, 2Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary, 3Institute of Bioanalysis, Medical School, University of Pécs, Pécs, Hungary, 4Division of Cardiology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary, 5Institute of Clinical Pharmacy, University of Szeged, Szeged, Hungary, 61st Department of Pediatrics, Semmelweis University, Budapest, Hungary, 7Heart Institute, Medical School, University of Pécs, Pécs, Hungary, 8Szentágothai Research Centre, University of Pécs, Pécs, Hungary, 9Centre for Translational Medicine, Semmelweis University, Budapest, Hungary, 10Division of Translational Medicine, Department of Internal Medicine, University of Szeged, Szeged, Hungary

Background: Mutations in the CACNA1C gene–encoding for the major Ca2+ channel of the heart–may exhibit a variety of clinical manifestations. These include typical or atypical Timothy syndromes (TS) which are associated with multiple organ manifestations, and cardiac involvement in form of malignant arrhythmias, QTc prolongation, or AV block. “Cardiac only” Timothy syndrome (COTS) shows no extracardiac manifestation, whereas some CACNA1C gene mutations are associated with QTc prolongation alone (isolated long QT syndrome 8, LQT8).

Methods: A systematic search of the literature reporting cases of CACNA1C gene mutation associated syndromes, including TS, COTS and isolated LQT8 via major databases published from 2004 through 2019 was performed. Detailed patient-level phenotypic and genotypic characteristics, as well as
long-term outcome measures were collected and compared between pre-specified patient groups, defined both on phenotype and genotype.

**Results:** A total of 59 TS, 6 COTS, and 20 isolated LQT8 index cases were identified. Apart of syndactyly or baldness, there were no major differences regarding clinical manifestations or outcome measures between TS subtypes, either defining TS subtypes on the genotype or based on the phenotype. Both subtypes were characterized by an extreme degree of QTc prolongation (median ≥ 600 ms) which were reflected in high major adverse cardiac event rate. On the other hand, there were marked differences between TS, COTS, and isolated LQT8. Timothy syndrome was characterized by a much earlier disease onset, much more pronounced QTc prolongation and much higher mortality rate than COTS or isolated LQT8. Similar differences were observed comparing CACNA1C exon 8/8A vs. non-exon 8/8A mutation carriers. TS showed a high degree of genetic homogeneity, as the p.Gly406Arg mutation either in exon 8 or exon 8A alone was responsible for 70% of the cases.

**Conclusions:** Clinical phenotypes associated with mutations in the CACNA1C gene show important clinical differences. Timothy syndrome is associated with the most severe clinical phenotype and with the highest risk of morbidity and mortality. However, distinguishing TS subtypes, in any form, are not supported by our data.

**Systematic review registration:** [https://www.crd.york.ac.uk/prospero/], identifier [CRD42020184737].

**KEYWORDS**
CACNA1C gene, Timothy syndrome, mortality, long QT syndrome, L-type calcium channel, mutation

**Introduction**

In cardiac myocytes, inwardly rectifying Ca$^{2+}$ current passes through the L-type calcium channel, the Ca$_{v}$1.2 voltage-gated calcium channel, thereby initiating calcium release through activation of ryanodine receptor 2 (RyR2) from the sarcoplasmic reticulum. The channel has several subunits, including the α1C-subunit, responsible for voltage sensing, for conduction pore formation, and for the gating mechanism. The fully functional channel complex is comprised of an additional intracellular β subunit and an extracellular α2δ subunit. The α1C subunit has 4 domains (I–IV), each with six transmembrane-spanning segments (S1–S6). S1–S4 are the voltage-sensitive subunits, whereas S5–S6 are the selectivity filter. When the membrane is depolarized, the S4 domain approaches the cytoplasmic ends of the S5 and S6 helices and the conduction pore opens. Changes in L-type calcium channel function (via phosphorylation, mutations, drugs, etc.) can affect cardiac myocyte contractility and arrhythmogenicity. The channel is expressed in many tissues of the body (1–3).

The α1C subunit of the channel is encoded by the CACNA1C gene. Mutations affecting the CACNA1C gene may exhibit a variety of clinical manifestations. These manifestations include the typical Timothy syndrome (Timothy syndrome 1, TS1), which is characterized by QTc prolongation, AV-block, congenital heart defects, facial dysmorphisms, episodic hypoglycemia and neurologic symptoms including developmental delays, possible autism, seizures, and intellectual disability. The most distinctive morphological hallmark of TS1 is syndactyly, in contrast to atypical Timothy syndrome (Timothy syndrome 2, TS2) patients, who have no syndactyly but carry many of the other multisystemic manifestations of the disease [recently reviewed by Bauer et al. (4)]. Further clinical manifestation of CACNA1C gene mutations include “cardiac only” Timothy syndrome (COTS) (5), which is characterized by QTc prolongation and congenital heart defects without extra-cardiac manifestations. In contrast to the above mentioned phenotypes, some CACNA1C gene mutations are associated with isolated QTc prolongation (isolated long QT syndrome 8, LQT8), exhibiting QTc prolongation only without additional cardiac or extra-cardiac manifestations (6–8). Because the
CACNA1C gene was the eighth gene proved to cause QTc prolongation, it was historically called LQT8, but today a clear distinction exists between multi-organ Timothy syndrome and isolated LQT8 (9).

These phenotypes are associated with a variety of CACNA1C gene mutations, affecting different regions of the CACNA1C gene. The predominant genetic cause of TS1, identified in 2004, is a recurrent, canonical "de novo" heterozygous missense mutation, p.Gly406Arg, in the alternatively spliced exon 8A (10). In cases with TS2, additional mutations, originally p.Gly406Arg and p.Gly402Ser, were identified in exon 8 of the gene (11). With the clinical description of "cardiac only" TS and isolated LQT8, an increasing number of CACNA1C mutations have been described in the literature. The accumulated data indicated a great amount of genetic and phenotypic heterogeneity of CACNA1C mutations associated phenotypes, i.e., "typical" TS mutations showing variant phenotypes (12) and "non-typical" TS mutations associated with typical TS phenotype (13–16) (Figure 1). Consequently, there is a high degree of controversy regarding the classification of CACNA1C gene associated phenotypes, especially regarding TS, mainly due to the lack of comparable outcome data (4).

Since TS is an extremely rare disease and most of the respective publications comprised only individual cases or case series, a systematic review of published data appears to be the best way to summarize the typical characteristics of this genetic disorder and to describe any possible correlations between the different phenotypes and clinical outcomes. Accordingly, the aim of the current work was to identify correlations between the mutations in different regions of the CACNA1C gene and various morphologic manifestations with different clinical outcomes. A special attention was made to the subject as to whether clinically meaningful differences exist among the different subtypes of Timothy syndrome.

Methods

This systematic review was reported in accordance with the PRISMA Statement for reporting systematic reviews and meta-analyses (17). Our predefined review protocol was published in the PROSPERO database under the registration number of CRD42020184737. There was no deviation from the predefined and published protocol during the study.

Systematic search

A comprehensive search was conducted in MEDLINE (via PubMed), Embase, Web of Science, and Scopus databases from 2004 through 2019 focusing on full-text papers published reporting data on patients with Timothy syndrome or isolated long QT syndrome 8 (LQT8) affected by mutations of the CACNA1C gene. Conference abstracts were included when same data could be extracted as from full-text papers. Studies eligible for inclusion were identified by using the following search query as full text search: "Timothy syndrome" OR ("LQT8 OR CACNA1C").

Eligibility criteria and selection

The eligibility criteria for this systematic review were as follows:

1) Reporting data on patients and/or relatives with documented mutation of the CACNA1C gene in the English language;
2) Describing detailed geno- and/or phenotypic features of the case;
3) Reporting data on clinical outcomes.

Reports on CACNA1C gene mutation associated Brugada syndrome (BrS3), short QT syndrome (SQT4) or early repolarization syndromes (ERS), exhibiting fundamentally different pathomechanisms, were excluded. Duplicate cases were identified, and the less informative ones were excluded. Two review authors independently evaluated all potentially relevant articles for eligibility. Any disagreement was subsequently resolved by consensus.

Data extraction

From the eligible reports, patient-level data were extracted. Beyond the detailed description of the mutation affecting the CACNA1C gene, the following sets of data has been extracted from the source reports (reported in more detail in Supplementary material): (1) Demographic data; (2) Manifestations of the disease (categorized as cardiac or extra-cardiac manifestations); (3) Utilized medical and device therapy; and (4) Outcome of the disease (categorized as death or cardiac events). Major adverse cardiac events (MACE) were defined as death, aborted cardiac arrest (ACA), sudden cardiac death (SCD), or appropriate ICD discharge. Arrhythmia type and circumstances at ACA/SCD/ICD discharge were also recorded if available.

Handling with aggregated data extracted from the original publication by Splawski et al. (10) is detailed in Supplementary material.

Patient groups

As there was a considerable overlap between genotypes and phenotypes, comparator groups have been defined both based on the genotype and based on the phenotype. Accordingly, patients were divided into the following groups, defined on the genotype:
FIGURE 1
Interrelation of different clinical phenotypes and genotypes in CACNA1C gene mutation associated diseases.

1) Carriers of exon 8A p.Gly406Arg CACNA1C mutations [formerly categorized as Timothy syndrome subtype 1 (TS1)] (4).
2) Carriers of exon 8 p.Gly406Arg CACNA1C mutations [formerly categorized as Timothy syndrome subtype 2 (TS2) in the strictest sense] (4).
3) Carriers of exon 8 p.Gly406Arg and p.Gly402Ser CACNA1C mutations [formerly categorized as Timothy syndrome subtype 2 (TS2), according to the original report] (11).
4) Carriers of all exon 8 CACNA1C mutations [including mutations p.Gly406Arg, p.Gly402Ser, p.Ser405Arg, p.Gly402Arg, and p.Pro381Ser mutations, formerly categorized as Timothy syndrome subtype 2 (TS2) in the broader sense].
5) Carriers of non-exon 8/8A CACNA1C mutations.

According to reported phenotypic manifestations patients were divided into the following three groups:

1) TS (Timothy syndrome, either typical or atypical, defined as patients with characteristic cardiac, and extra-cardiac manifestations). Two subgroups, i.e., typical TS (defined as patients with syndactyly) and atypical TS (defined as patients without syndactyly) were also analyzed separately.
2) Cardiac only TS (COTS, defined as patients with cardiac manifestations only).
3) Isolated long-QT syndrome 8 (LQT8, defined as patients with QTc prolongation only).

Proven mosaic TS cases, reported as such, present in very small numbers in the reported publications, were not considered, taking the very specific genetic constellation of these cases into consideration.

For all the comparator groups two sets of comparisons were made: (i) including index patients only (i.e., one affected person per family) (ii) including all affected patients (i.e., including index patients and all affected family members).

Re-evaluation of the interpretation of different CACNA1C mutations

As many of the considered publications were published before the standards for the interpretation of sequence variants were issued by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
(ACMG/AMP) in 2015, (18) we reassessed the interpretations of all extracted CACNA1C mutations. All the mutations were re-evaluated in ClinVar1 and Varsome.2

Statistical analysis

For descriptive statistics the number of cases and percentage were calculated for each group in case of categorical and median and interquartile range in case of continuous variables. The differences between groups in case of categorical variables were examined using the Chi-square test and Fisher's exact test. For continuous outcomes, because of the origin of the data, non-parametric methods, such as Mann–Whitney U-test or the Kruskal–Wallis test was used to detect differences between groups. A p < 0.05 value was considered as statistically significant. All calculation was made by IBM SPSS statistical software (IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY, USA: IBM Corp.).

Results

Study and patient characteristics

Excluding reports on mosaic patients, (19–23) a total of 34 publications comprising data of 134 patients were identified and formed the basis of this systematic review (Figure 2 and Table 1). Most of the publications reported data of one case, whereas 16 studies summarized genotypic and clinical data of more patients/pedigrees.

Out of the 134 patients, there were 85 index patients and 49 additional family members. Out of the 85 index patients 59 suffered from TS, 6 from COTS and 20 from isolated LQT8, respectively. In the entire patient population (index patients and relatives), there were 60 patients with TS, 15 patients with COTS and 59 patients with isolated LQT8 (Table 2).

Re-evaluation of the interpretation of different CACNA1C mutations

Altogether, 33 CACNA1C mutations were extracted from the reports (Table 3). Twenty-eight mutations (85%) had an interpretation of pathogenic (P), likely pathogenic (LP), or variant of unknown significance (VUS) favoring P/LP, either according to ClinVar or Varsome. In general, the number of ClinVar submissions were low (1–4 submissions). Only five mutations (p.Ala28Thr, p.Met456Ile, p.Gly1783Cys, p.Arg1906Gln, p.Gly1911Arg) had a verdict of benign (B), likely benign (LB), or VUS. However, in the case of p.Ala28Thr, reported familial segregation of the mutation in affected family members and functional studies providing evidence for deleterious effect (6) were not considered in the Varsome algorithm which would activate an additional PP1 and a PS3 criteria shifting the interpretation of the variant as VUS favoring LP. Also, for the p.Gly1911Arg variant, reported to be associated with TS, significant differences in the functional analysis and “de novo” occurrence of the variant have been demonstrated, (15) activating a PS2 and PS3 criteria and shifting the interpretation of the variant as VUS favoring P. In the case of the p.Met456Ile, Gly1783Cys and Arg1906Gln variants, all reported to be associated with isolated LQT8, no significant additional features (e.g., differences in the functional analysis, familial segregation, etc.) were demonstrated to alter the Varsome verdict. However, for the sake of data integrity all the mutations with the reported phenotypes were considered as they were reported.

Comparison of patient groups defining different subgroups of Timothy syndrome

Comparison of different subgroups of Timothy syndrome, defined on genotype (patients with exon 8A p.Gly406Arg vs. exon 8 p.Gly406Arg mutations; vs. exon 8 p.Gly406Arg/p.Gly402Ser mutations, vs. all exon 8 mutations)

There were 31 index pts. with exon 8A mutations (all carriers of canonical p.Gly406Arg mutation), 6 pts. with exon 8 p.Gly406Arg mutations, 12 pts. with exon 8 p.Gly406Arg/p.Gly402Ser mutations and 16 pts. with exon 8 mutations (six p.Gly406Arg, six p.Gly402Ser, two p.Ser405Arg, one p.Gly402Arg and one p.Pro381Ser mutations). In further five patients (all carriers of the p.Gly406Arg mutation) it was not unequivocally reported and was impossible to determine whether the patients carried the p.Gly406Arg mutation in exon 8 or in exon 8A. (24–28) (Table 3 and Figure 3).

The detailed comparison of the groups is presented in Table 4. Comparing data on demographics, clinical and ECG manifestations, and outcome, it was only syndactyly which was significantly more frequent in pts. with exon 8A p.Gly406Arg mutations in all comparisons, and baldness which was again more frequent in pts. with exon 8A p.Gly406Arg mutations in comparison with pts. carrying exon 8 p.Gly406Arg/Gly402Ser mutations or all exon 8 mutations. The presence of AV block was also more frequent and the age at MACE was lower in pts. with exon 8A p.Gly406Arg mutations in comparison with pts. with all exon 8 mutations. In addition, patients with exon 8A p.Gly406Arg mutations were significantly younger at the time of diagnosis (median 0 vs. 32 months; p = 0.019) and more pts. were diagnosed in the first year of life (89 vs. 44%; p = 0.009).
FIGURE 2
Flow chart of study selection.

Total references identified through database search
(PubMed: n=98; EMBASE: n=222; Web of Science: n=180; Scopus: n=187)

n=687

References after removal of duplicates

n=204

Records screened

n=204

Excluded as incomplete abstract or title unsuitable

n=155

Potentially relevant publications assessed for eligibility

n=49

Reports excluded:

n=12
No clinical features (n=2)
No genetic data (n=3)
Reports in Russian, Portuguese (n=2)
Duplicate patients (n=4)
Conference abstracts (n=1)

Case studies included in systematic review (1 case records: n=21; pedigree records: n=16)

n=37

Included

Studies on TS patients

n=22

Studies on mosaic TS patients

n=3

Studies on COTS patients

n=3

Studies on LQT8 patients

n=4

Studies on TS & mosaic TS COTS & LQT8 patients

n=5
TABLE 1  Main characteristics of the reports included in the study.

| References          | Year of report | Origin of report | Reported number of index patients | Reported disease phenotype | Reported CACNA1C_mutation   |
|---------------------|----------------|------------------|-----------------------------------|---------------------------|-----------------------------|
| Splawski et al. (10)| 2004           | United States    | 13                                | TS                        | Gly406Arg                   |
| Lo-A-Njoe et al. (38)| 2005           | Netherlands      | 2                                 | TS                        | Gly406Arg                   |
| Splawski et al. (11)| 2005           | United States    | 2                                 | TS                        | Gly406Arg, Gly402Ser         |
| Jacobs et al. (39)  | 2006           | United States    | 1                                 | TS                        | Gly402Ser                   |
| Krause et al. (25)  | 2011           | Germany          | 1                                 | TS                        | Gly406Arg                   |
| Gillis et al. (13)  | 2012           | Canada           | 1                                 | TS                        | Ala1473Gly                  |
| An et al. (60)      | 2013           | South Korea      | 1                                 | TS                        | Gly406Arg                   |
| Boczek et al. (6)   | 2013           | United States    | 4                                 | LQT8                      | P381S, M456I, A582D, R858H, G1783C |
| Gao et al. (23)     | 2013           | China            | 1                                 | TS                        | Gly406Arg                   |
| Frohler et al. (22) | 2014           | Lebanon          | 1                                 | TS                        | Gly402Ser                   |
| Fukuyama et al. (7) | 2014           | Japan            | 7                                 | LQT8                      | Gly406Arg                   |
| Hennessey et al. (15)| 2014         | Philippines      | 1                                 | TS                        | G1911R                       |
| Boczek et al. (14)  | 2015           | United States    | 4                                 | COTS: 3, TS: 1             | Arg518Cys, Arg518His, Ile1166Thr |
| Corona-Rivera et al. (41)| 2015       | Mexico           | 1                                 | TS                        | Gly406Arg                   |
| Diep and Seaver (30)| 2015           | Hawaii           | 1                                 | TS                        | Gly406Arg                   |
| Ergol et al. (42)   | 2015           | Turkey           | 1                                 | TS                        | Gly406Arg                   |
| Hiippala et al. (43)| 2015           | Finland          | 2                                 | COTS: 1, LQT8: 1           | Gly406Arg, Gly402Ser         |
| Wemhoner et al. (6) | 2015           | Germany          | 6                                 | TS: 1, LQT8: 5             | Ala28Thr, Ile1166Val, Ile1475Met, Arg860Gly, Ile1166Thr, Gly1496Lys |
| Gunay et al. (44)   | 2016           | Turkey           | 1                                 | TS                        | Ala1473Gly                  |
| Kawaida et al. (24) | 2016           | Japan            | 1                                 | TS                        | Gly406Arg                   |
| Landstrom et al. (26)| 2015          | Hispanic         | 1                                 | LQT8                      | Leu762Phe                   |
| Landstrom et al. (26)| 2016          | Hispanic         | 1                                 | TS                        | Gly406Arg                   |
| Philipp and Rodriguez (45)| 2016     | United States    | 1                                 | TS                        | Gly406Arg                   |
| Sepp et al. (12)   | 2017           | Hungary          | 1                                 | TS                        | Gly406Arg                   |
| Dufendach et al. (29)| 2018          | United States    | 16                                | TS                        | Gly402Ser, Gly406Arg, Ser405Arg, Gly402Arg, Lys1211Glu, Cys1021Arg |
| Gardner et al. (46) | 2018           | New Zealand      | 1                                 | LQT8                      | Arg518His                   |
| Kojima et al. (47)  | 2018           | Japan            | 1                                 | COTS                      | K1580T                      |
| Kosaki et al. (16)  | 2018           | Japan            | 1                                 | TS                        | Arg5124Hly                  |
| Ozawa et al. (34)   | 2018           | Japan            | 1                                 | TS                        | Ser463F                     |
| Seo et al. (48)     | 2018           | South Korea      | 1                                 | COTS                      | Arg518Cys                   |
| Tunca Sahin and Ergul (27)| 2018      | Turkey           | 1                                 | TS                        | Gly406Arg                   |
| Walsh et al. (49)   | 2018           | United Kingdom   | 5                                 | TS                        | Gly406Arg                   |
| Ye et al. (33)      | 2018           | United States    | 1                                 | LQT8                      | E1115K                      |
| Colson et al. (50)  | 2019           | France           | 1                                 | TS                        | Gla407Ala                   |

Marked QTc prolongation (> 500 ms) was present in all the patients, except two patients with exon 8 mutation. The degree of QTc prolongation (maximum QTc) was similar in the groups (median ≥600 ms in all groups). There was no difference in the utilization of pacemaker/ICD implantation or of left cervical sympathectomy. MACE rate was high (67–83%) but was not different in the groups.

Comparison of different subgroups of Timothy syndrome, defined on phenotype (Timothy syndromes with or without syndactyly)

The detailed comparison of the groups is presented in Table 4. There were 45 TS pts. with syndactyly and 14 pts. without syndactyly. Only baldness was more frequent and the age at MACE was lower in TS pts. with syndactyly. The degree
**TABLE 2** Patients included into the comparator groups of the study.

| Genotype | Phenotype                  | Total |
|----------|----------------------------|-------|
|           | COTS LQT8                  |       |
| CACNA1C   | TS                         | 31    |
| exon 8    |                            | 6     |
| p.Gly406Arg mutation carrier |           |
|           |                            | 31    |
| CACNA1C   | TS with syndactyly         | 12    |
| exon 8    |                            | 16    |
| p.Gly406Arg/p.Gly402Ser mutation carrier |         |
|           |                            | 13    |
| CACNA1C   | TS without syndactyly      | 17    |
| non-exon 8/8A mutation carrier |         |
|           |                            | 81    |
| Timothysyndrome (TS) COTS LQT8 |         |
|           | TS with syndactyly         | 46    |
| TS without syndactyly |           |
|           | TS total sydactyly         | 14    |
| TS total syndactyly |               |
|           |                            | 59    |
| all patients*, n |           | 85    |
| *Including family members. |         |
| †In 5 patients (all carriers of the p.Gly406Arg mutation) it was not reported whether the patients carried the p.Gly406Arg mutation in exon 8 or in exon 8A. | |
| ‡Exon 8A mutations carriers all carried the p.Gly406Arg mutation. | |

Analysis of all patients, including family members

There was one additional family member with exon 8 mutation. His inclusion did not alter any of the statistical comparisons.

**Comparison of patient groups defining different forms of CACNA1C gene associated diseases**

Comparison of different forms of CACNA1C gene associated diseases, defined on genotype (patients with exon 8/8A CACNA1C mutations vs. non-exon 8/8A CACNA1C mutations)

There were 52 index patients with exon 8/8A and 33 index patients with non-exon 8/8A mutations. Exon 8/8A mutations almost all clustered at codon 402 (7 cases), 405 (2 cases), and 406 (42 cases), while the most frequently affected codons in non-exon 8/8A mutation carriers were codon 518 (three cases with p.Arg518Cys mutations and one case with p.Arg518His mutation), codon 857 (one case with p.Pro857Leu and p.Pro857Arg mutations each), codon 858 (four cases with p.Arg858His mutation), codon 1166 (two cases with p.Ile1166Thr, and one case with Ile1166Val mutation) and codon 1473 (two cases with p.Ala1473Gly mutation) (**Table 3** and **Figure 3**).

The detailed comparison of the two groups is presented in **Table 5**. Patients with exon 8/8A mutations were significantly younger at the time of diagnosis, and a higher percentage of the patients were diagnosed at birth or in the first year of life.

The predominant phenotype associated with exon 8/8A mutations was TS in 49 patients (96%), COTS in 1 patient (2%) and isolated LQT8 in 2 patient (2%), while with non-exon 8/8A mutations it was TS in 10 patients (29%), COTS in 5 patients (15%) and isolated LQT8 in 18 patients (56%) (p < 0.001). Extra-cardiac manifestations (94 vs. 32%; p < 0.001) were significantly more frequent in patients with exon 8/8A mutations. As TS was the overwhelmingly prevalent phenotype in patients with exon 8/8A mutations, the major phenotypic characteristics of TS were all significantly more frequent in patients with exon 8/8A mutations. QTc prolongation was present in all the 52 patients with exon 8/8A mutations, while it was seen in only in 79% of the patients with non-exon 8/8A mutations (p = 0.0025). The degree of QTc prolongation (maximum QTc) was much more pronounced in patients with exon 8/8A mutations (median 606 vs. 498 ms.; p < 0.0001) and the rate of pts. with >500 ms QTc prolongation was much higher (92 vs. 36%; p < 0.001). AV block was also observed in significantly more cases in patients with
| Exon | Codon | Mutation | ClinVar | Varsome | TS \(n = 59\) | COTS \(n = 6\) | LQT8 \(n = 20\) | Total \(n = 85\) |
|------|-------|----------|---------|---------|-------------|-------------|--------------|---------------|
|      |       |          | Verdict | Max  | Score | Submiss. | Verdict | Items | n % | n % | n % | n % | n % |
| 2    | 28    | Ala28Thr | VUS     | 3    | 3     | 1       | Likely benign | BS2 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 8    | 381   | Pro381Ser | VUS     | 3    | 3     | 1       | VUS-favoring LP | PM2, PP3, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 402  | Gly402Arg | VUS     | 3    | 3     | 1       | VUS-favoring P | PM2, PP3, PP5, BP1 | 1  | 2%  | 0  | 0%  | 0  | 0%  | 2  | 10% |
| 402  | Gly402Ser | P       | 5    | 4.6   | 3       | Likely pathogenic | PP5, PM2, P3, BP1 | 5  | 8%  | 0  | 0%  | 1  | 5%  | 6  | 7%  |
| 405  | Ser405Arg | ND      |      |       |         | Likely pathogenic | PP3, PM2, BP1 | 2  | 3%  | 0  | 0%  | 0  | 0%  | 2  | 2%  |
| 406  | Gly406Arg | P       | 5    | 5     | 3       | Pathogenic | PS1, PP3, PP5, PM2, BP1 | 6  | 10% | 0  | 0%  | 0  | 0%  | 6  | 7%  |
| 8A   | Gly406Arg | P       | 5    | 5     | 3       | Pathogenic | PS1, PP3, PP5, PM2, BP1 | 31  | 53% | 0  | 0%  | 0  | 0%  | 31 | 36% |
| 8/8A?| Gly406Arg | P       | 5    | 5     | 3       | Pathogenic | PS1, PP3, PP5, PM2, BP1 | 4   | 7%  | 1  | 17% | 0  | 0%  | 5  | 6%  |
| 9    | Gln407Ala | ND      |      |       |         | VUS-favoring LP | PM2, PP3, BP1 | 1  | 2%  | 0  | 0%  | 0  | 0%  | 1  | 1%  |
| 456  | Met456Val | ND      |      |       |         | VUS-favoring LP | PM2, PP3, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 518  | Arg518Cys | P       | 5    | 5     | 2       | Likely pathogenic | PP5, PM2, PM5, PP3, BP1 | 0  | 0%  | 3  | 50% | 0  | 0%  | 3  | 4%  |
| 518  | Arg518His | P       | 5    | 4.7   | 3       | Likely pathogenic | PP5, PM2, PM5, PP3, BP1 | 0  | 0%  | 1  | 17% | 0  | 0%  | 1  | 1%  |
| 582  | Ala582Asp | P       | 5    | 5     | 1       | Likely pathogenic | PS3, PM2, PP3, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 643  | Ser643Pro | ND      |      |       |         | VUS-favoring LP | PM2, PP3, BP1 | 1  | 2%  | 0  | 0%  | 0  | 0%  | 1  | 1%  |
| 762  | Leu762Pro | LP      | 4    | 4     | 1       | VUS-favoring LP | PM2, PP3, PP5, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 834  | Lys834Glu | P       | 5    | 5     | 1       | Likely pathogenic | PS3, PM2, PP3, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 857  | Pro857Arg | P       | 5    | 5     | 1       | Likely pathogenic | PS3, PM2, PP3, BP1 | 0  | 0%  | 1  | 17% | 0  | 0%  | 1  | 1%  |
| 857  | Pro857Leu | LP      | 5    | 4     | 3       | VUS-favoring P | PM2, PM5, PP3, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 858  | Arg858His | P       | 5    | 4.7   | 4       | VUS-favoring P | PM2, PM5, PP3, BP1 | 0  | 0%  | 4  | 20% | 0  | 0%  | 4  | 5%  |
| 860  | Arg860Gly | P       | 5    | 5     | 1       | VUS-favoring LP | PM2, PP3, PP5, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 1021 | Cys1021Arg | VUS    | 3    | 3     | 1       | Likely pathogenic | PM2, PP3, BP1 | 1  | 2%  | 0  | 0%  | 0  | 0%  | 1  | 1%  |
| 1024 | Arg1024Gly | ND     |      |       |         | VUS-favoring LP | PM2, PP3, BP1 | 1  | 2%  | 0  | 0%  | 0  | 0%  | 1  | 1%  |
| 1115 | Gln1115Lys | VUS    | 3    | 3     | 1       | Likely pathogenic | PM2, PP3, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 1166 | Ile1166Thr | P       | 5    | 5     | 1       | Likely pathogenic | PM2, PP3, PP5, BP1 | 2  | 3%  | 0  | 0%  | 0  | 0%  | 2  | 2%  |
| 1166 | Ile1166Val | ND     |      |       |         | VUS-favoring LP | PM2, PP3, PP5, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 1211 | Lys1211Glu | VUS    | 3    | 3     | 1       | VUS-favoring LP | PM2, PP3, PP5, BP1 | 1  | 2%  | 0  | 0%  | 0  | 0%  | 1  | 1%  |
| 1475 | Ile1475Met | P       | 5    | 5     | 1       | Likely pathogenic | PM2, PP3, PP5, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 1496 | Gln1496Lys | ND     |      |       |         | VUS-favoring LP | PM2, PP3, BP1 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 1473 | Ala1473Gly | LP      | 5    | 4.5   | 2       | VUS-favoring LP | PM2, PP3, PP5, BP1 | 2  | 3%  | 0  | 0%  | 0  | 0%  | 2  | 2%  |
| 1580 | Lys1580Thr | ND     |      |       |         | VUS-favoring LP | PM2, PP3, BP1 | 0  | 0%  | 1  | 17% | 0  | 0%  | 1  | 1%  |
| 1783 | Gly1783Cys | VUS    | 3    | 3     | 1       | Likely benign | PM2, BP1, BP4 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 1906 | Arg1906Gln | VUS    | 3    | 3     | 8       | Benign | BS1, BS2, PP3 | 0  | 0%  | 0  | 0%  | 1  | 5%  | 1  | 1%  |
| 1911 | Gly1911Arg | VUS    | 3    | 3     | 3       | Benign | BS1, BS2 | 1  | 2%  | 0  | 0%  | 0  | 0%  | 1  | 1%  |

A score for all the ClinVar entries were assigned [benign (B): 1, likely benign (LB): 2, variant of unknown significance (VUS): 3, likely pathogenic (LP): 4, pathogenic (P): 5], and the average of the scores were taken into consideration. A score of > 4.5 indicated P variants, and a score between 3.5 and 4.5 indicated LP and between 2.5 and 3.5 indicated VUS variants, respectively. ND: no data, TS: Timothy syndrome, COTS: "cardiac only" Timothy syndrome, LQT8: isolated long QT syndrome subtype 8.
exon 8/8A mutations (74 vs. 33%; \( p = 0.002 \)). There was no difference in the utilization of pacemaker/ICD implantation or of left cervical sympathectomy. There was a marked difference in terms of outcome, as much higher number of pts. with exon 8/8A mutations died (33 vs. 9%; \( p = 0.017 \)) or experienced MACE (71 vs. 34%; \( p = 0.001 \)).

Comparison of different forms of CACNA1C gene associated diseases, defined on phenotype (patients with Timothy syndromes vs. “cardiac only” Timothy syndrome vs. isolated LQT8)

Out of the 85 index patients there were 59 (69%) with TS, 6 (7%) with COTS and 20 (24%) with the isolated LQT8 phenotype.

As detailed previously, exon 8 or 8A mutations, affecting codons 402, 405 and 406 made up the majority of the genotypes in patients with TS (49/59 patients, 83%). Most mutations leading to COTS affected codon 518 in 4/6 patients (67%). Mutations causing isolated LQT8 scattered through the gene with only one codon having affected in more than one patient (codon 858 in 4/20 patients, 20%) (Table 3 and Figure 3).

The detailed comparison of the three groups is presented in Table 5. Patients with TS were significantly much younger at the time of diagnosis than patients with COTS or isolated LQT8 (median 1 month vs. 180 months vs. 174 months, respectively; \( p < 0.001 \)). In addition, significantly much more pts. with TS were diagnosed at birth or in the first year of life. The degree of QTc prolongation was much more prominent in patients with TS than in patients with COTS or with isolated LQT8 (median 603 vs. 490 vs. 480 ms, respectively; \( p < 0.001 \)) and the number of pts. with >500 ms QTc prolongation was much higher (94 vs. 17% vs. 20%, respectively; \( p < 0.001 \)). There was no significant difference regarding PM/ICD/AED implantation or utilization of left cervical sympathectomy among the groups.

There was a marked difference in terms of outcome, as a much higher number of pts. with TS died, as compared with COTS, or isolated LQT8 (32 vs. 17% vs. 0%, respectively; \( p = 0.006 \)) or experienced MACE (71 vs. 33% vs. 30%, respectively; \( p = 0.004 \)).

Analysis of all patients, including family members

There was one additional family member with exon 8/8A mutations (total of 53 patients) and additional 48 family members with non-exon 8/8A mutations (total of 81 patients), and there was one additional family member with TS (total of 60 cases), 9 family members with COTS (total of 15 cases) and 39 family members with isolated LQT8 (total of 59 cases).

As family members in every group usually exhibited a milder phenotype, all the statistical differences, observed...
### TABLE 4: Comparison of clinical characteristics and outcome data in the index patients in Timothy syndrome subtypes.

| CACNA1C exon 8A Gly406Arg mutation carrier | CACNA1C exon 8 Gly406Arg mutation carrier | p | CACNA1C exon 8 Gly406Arg/Gly402Ser mutation carrier | CACNA1C all exon 8 mutation carrier | p | TS with syndactyly n = 45 | TS w/o syndactyly n = 14 | p |
|-------------------------------------------|------------------------------------------|---|-------------------------------------|-------------------------------|---|------------------------|------------------------|---|
| Demographics                              |                                          |   |                                     |                               |   |                        |                         |   |
| Age at diagnosis, months [median (IQR)]    | 0 (0–11)                                 | 0.378 | 5 (0–51)                           | 0.189                        | 32 (0–63) | 0.019 | 6 (0–24) | 0 (0–41) | 0.721 |
| Diagnosis at birth, n (%)                 | 10/18 (55.6)                             | 0.351 | 5/12 (41.7)                        | 0.710                        | 5/16 (31.2) | 0.185 | 14/32 (43.7) | 9/14 (64.3) | 0.205 |
| Diagnosis in first year of life, n (%)    | 16/18 (88.9)                             | 1.000 | 7/12 (58.3)                        | 0.084                        | 7/16 (43.7) | 0.099 | 23/32 (71.9) | 9/14 (64.3) | 0.611 |
| Sex (M/F)                                 | 15/9                                      | 0.360 | 4/6                                 | 0.276                        | 4/7 | 0.156 | 16/18 | 8/3 | 0.143 |
| Disease manifestation                      |                                          |   |                                     |                               |   |                        |                         |   |
| Extra cardiac manifestations, n (%)       |                                          | NA |                                     | NA                           | 14/16 (93.3) | 0.111 | NA |                         |   |
| Syndactyly, n (%)                         | 29/31 (93.5)                             | 1.000 | 4/12 (33.3)                        | 0.000                        | 6/16 (37.5) | 0.000 | NA |                         |   |
| Baldness, n (%)                           | 18/23 (78.3)                             | 0.430 | 1/5 (20)                           | 0.026                        | 1/8 (12.5) | 0.002 | 21/27 (77.8) | 2/7 (20.6) | 0.024 |
| Facial abnormality, n (%)                 | 7/13 (53.8)                              | 1.000 | 6/12 (50)                          | 1.000                        | 6/16 (37.5) | 0.467 | 14/23 (60.9) | 8/14 (57.1) | 1.000 |
| Seizures, n (%)                           | 3/6 (50)                                 | 1.000 | 2/7 (28.6)                         | 0.592                        | 2/8 (25.0) | 0.580 | 5/9 (55.6) | 5/9 (55.6) | 1.000 |
| Neuro developmental delay, n (%)          | 7/11 (63.6)                              | 0.245 | 8/11 (72.7)                        | 1.000                        | 10/15 (66.7) | 1.000 | 15/21 (70.6) | 9/12 (55.0) | 1.000 |
| Baldness, n (%)                           | 12 (50)                                  | 1.000 | 2/2 (100)                          | 1.000                        | 0/1 (0.0) | 1.000 | 1/3 (33.3) | 1.000 |
| Facial abnormality, n (%)                 | 3/4 (75)                                 | 1/2 (50) | 2/5 (40)                          | 0.524                        | 2/6 (33.3) | 0.524 | 4/6 (66.7) | 2/4 (50.0) | 1.000 |
| Seizures, n (%)                           | 14/15 (93.3)                             | 1.000 | 1/2 (50)                           | 0.228                        | 1/3 (33.3) | 0.056 | 14/14 (100) | 3/5 (60.0) | 0.058 |
| Hypocalcemia, n (%)                       | 0/1 (0.0)                                | 1/1 (100) | 1/1 (100)                         | 1.000                        | 1/2 (100) | 1.000 | 1/1 (100) | 1/2 (50.0) | 1.000 |
| Hypoglycemia, n (%)                       | 1/14 (57.1)                              | 0.500 | 2/5 (40)                           | 0.628                        | 2/9 (22.2) | 0.197 | 9/20 (45.0) | 4/7 (57.1) | 0.678 |
| Orthopedic disorder, n (%)                | 0/1 (0.0)                                | 0.250 | 4/4 (100)                          | 0.020                        | 4/5 (80.0) | 0.333 | 3/3 (100) | 5/6 (83.3) | 1.000 |
| ECG and arrhythmia manifestations         |                                          |   |                                     |                               |   |                        |                         |   |
| Max. QTc, ms [median (IQR)]               | 600 (570–650)                            | 0.639 | 610 (555–699)                      | 0.655                        | 603 (555–681) | 0.500 | 603 (570–650) | 610 (554–702) | 0.991 |
| QTc > 500 ms, n (%)                       | 17/18 (94.4)                             | 1.000 | 11/12 (91.7)                       | 1.000                        | 14/16 (87.5) | 0.484 | 30/32 (93.7) | 13/14 (92.9) | 0.911 |

(Continued)
## TABLE 4 (Continued)

|                      | CACNA1C exon 8A Gly406Arg mutation carrier (n = 31) | CACNA1C exon 8 Gly406Arg mutation carrier (n = 6) | p    | CACNA1C exon 8 Gly406Arg/Gly402Ser mutation carrier (n = 12) | p    | CACNA1C all exon 8 mutation carrier (n = 16) | p     | TS with syndactyly (n = 45) | TS w/o syndactyly (n = 14) | p     |
|----------------------|-------------------------------------------------|------------------------------------------------|------|------------------------------------------------|------|--------------------------------|-------|-----------------------------|-----------------------------|-------|
|                      | vs. exon 8A Gly406Arg mutation carrier           |                                                  |      |                                                  |      |                                              |       |                             |                             |       |
| AV block, n (%)      | 27/31 (87.1)                                    | 6/6 (100)                                       | 1.00 | 7/11 (63.6)                                     | 0.174| 7/15 (46.7)                                   | 0.009 | 34/43 (79.1)                 | 9/13 (69.2)                 | 0.472 |
| Syncope, n (%)                         | 1/3 (33.3)                                      | 2/2 (100)                                       | 0.400| 4/4 (100)                                      | 0.143| 4/4 (100)                                    | 0.143 | 3/4 (75.0)                  | 4/5 (80.0)                  | 1.000 |
| T wave alternans, n (%)                  | 9/14 (64.3)                                     | 5/6 (83.3)                                      | 0.613| 7/12 (58.3)                                     | 1.000| 9/15 (60.0)                                   | 1.000 | 16/21 (76.2)                | 6/12 (50.0)                 | 0.149 |
| Documented major arrhythmia NOT leading to ACA/SCD/ICDD, n (%)               | 11/21 (52.4)                                    | 4/6 (66.7)                                      | 0.662| 5/9 (55.6)                                      | 0.875| 13/30 (43.3)                                  |       |                             |                             | 0.169 |
| **Devices and interventions**             |                                                |                                                |      |                                                |      |                                              |       |                             |                             |       |
| PM, n (%)                        | 5/11 (45.5)                                     | 4/5 (80.0)                                      | 0.308| 6/9 (66.7)                                     | 0.406| 6/9 (66.7)                                    | 0.406 | 9/18 (50.0)                 | 7/10 (70.0)                 | 0.434 |
| ICD/AED, n (%)                   | 11/18 (61.1)                                    | 3/6 (50.0)                                      | 0.665| 9/12 (75)                                      | 0.694| 11/15 (73.3)                                  | 0.712 | 19/29 (65.5)                | 9/14 (64.3)                 | 1.000 |
| LCSD, n (%)                      | 3/18 (16.7)                                     | 1/6 (16.7)                                      | 1.000| 1/12 (8.3)                                      | 0.632| 1/15 (6.7)                                    | 0.607 | 3/28 (10.7)                 | 2/14 (14.3)                 | 1.000 |
| **Outcome**                      |                                                |                                                |      |                                                |      |                                              |       |                             |                             |       |
| Death, n (%)                    | 13/31 (41.9)                                    | 2/6 (33.3)                                      | 1.000| 2/12 (16.7)                                     | 0.164| 2/16 (12.5)                                   | 0.052 | 16/45 (35.6)                | 3/14 (21.4)                 | 0.514 |
| Age at death, months [median (IQR)] | 3 (1–25)                                       | 37 (–)                                          | 0.434| 37 (–)                                          | 0.434| 37                                            | 0.434 | 2 (1–18)                   | 44                          | 0.102 |
| Major adverse cardiac event (death/ACA/SCD/ICDD), n (%)                  | 22/31 (71.0)                                    | 4/6 (66.7)                                      | 1.000| 10/12 (83.3)                                    | 0.698| 11/16 (68.7)                                  | 0.876 | 30/44 (68.2)                | 10/14 (71.4)                | 1.000 |
| Age at MACE, months [median (IQR)]   | 24 (2–29)                                       | 45 (16–66)                                      | 0.151| 54 (16–72)                                      | 0.062| 54 (16–72)                                    | 0.034 | 17 (2–30)                  | 60 (46–72)                  | 0.003 |

Statistically different differences are indicated in bold. ASD, autism spectrum disorder; PM, pacemaker; ICD, implantable automated defibrillator; AED, automatic external defibrillator; LCSD, left cervical sympathetic denervation; TS, Timothy syndrome; COTS, “cardiac only” Timothy syndrome; LQTS, isolated long QT syndrome, subtype 8.
| CACNA1C exon 8/8A mutation carrier | CACNA1C non-exon 8/8A mutation carrier | p | TS n = 59 | COTS n = 6 | LQT8 n = 20 | p |
|----------------------------------|---------------------------------------|---|-----------|-----------|-------------|---|
| **Demographics**                 |                                       |   |           |           |             |   |
| Age at diagnosis, months [median (IQR)] | 2 (0–30) | 144 (33–270) | <0.001 | 1 (0–30) | 180 (30–534) | 174 (144–318) | <0.001 |
| Diagnosis at birth, n (%) | 19/39 (48.7) | 5/31 (16.1) | 0.005 | 23/46 (50.0) | 1/4 (25.0) | 0/20 (0.0) | 0.000 |
| Diagnosis in first year of life, n (%) | 27/39 (69.2) | 6/31 (19.4) | <0.001 | 32/46 (69.6) | 1/4 (25.0) | 0/20 (0.0) | <0.001 |
| Sex (M/F) | 19/21 | 13/18 | 0.643 | 24/21 | 3/3 | 5/15 | 0.096 |
| **Disease manifestation** |                                       |   |           |           |             |   |
| Extra cardiac manifestation, n (%) | 49/52 (94.2) | 10/31 (32.3) | 0.000 |           |           |           |           |
| Syndactyly, n (%) | 39/52 (75.0) | 5/28 (17.9) | 0.000 |           |           |           |           |
| Baldness, n (%) | 20/32 (62.5) | 3/23 (13.0) | 0.000 |           |           |           |           |
| Facial abnormality, n (%) | 15/31 (48.4) | 7/27 (25.9) | 0.106 |           |           |           |           |
| Seizures, n (%) | 5/14 (35.7) | 6/26 (23.1) | 0.469 |           |           |           |           |
| Neuro developmental delay, n (%) | 18/28 (64.3) | 6/26 (23.1) | 0.003 |           |           |           |           |
| Autism/ASD, n (%) | 0/5 (0.0) | 2/21 (9.5) | 1.000 |           |           |           |           |
| Recurrent infections, n (%) | 5/10 (50.0) | 1/21 (4.8) | 0.007 |           |           |           |           |
| Dental abnormalities, n (%) | 15/18 (83.3) | 2/21 (9.5) | 0.000 |           |           |           |           |
| Hypocalcemia, n (%) | 1/3 (33.3) | 1/20 (5.0) | 0.249 |           |           |           |           |
| Hypoglycemia, n (%) | 11/24 (45.8) | 2/25 (8.0) | 0.004 |           |           |           |           |
| Orthopedic disorder, n (%) | 4/6 (66.7) | 4/23 (17.4) | 0.033 |           |           |           |           |
| **ECG and arrhythmia manifestations** |                                       |   |           |           |             |   |
| Max. QTc, ms [median (IQR)] | 606 (570–654) | 498 (475–534) | <0.001 | 603 (566–655) | 490 (480–500) | 480 (451–498) | <0.001 |
| QTc > 500 ms, n (%) | 36/39 (92.3) | 12/33 (36.4) | 0.000 | 43/46 (93.5) | 1/6 (16.7) | 4/20 (20.0) | <0.001 |
| AVblock, n (%) | 38/51 (74.5) | 6/18 (33.3) | 0.002 | 43/56 (76.8) | 1/2 (50.0) | 0/11 (0.0) | <0.001 |
| Syncope, n (%) | 5/7 (71.4) | 10/13 (76.9) | 1.000 | 7/9 (77.8) | 0/2 (0) | 8/9 (88.9) | 0.101 |
| T wave alternans, n (%) | 20/31 (64.5) | 5/9 (55.6) | 0.705 | 22/33 (66.7) | 1/2 (50.0) | 2/5 (40.0) | 0.437 |
| Documented major arrhythmia NOT leading to ACA/SCD/ICDD, n (%) | 16/34 (47.1) | 6/23 (26.1) | 0.114 | 20/40 (50.0) | 1/4 (25.0) | 1/13 (7.7) | 0.111 |
| **Devices and interventions** |                                       |   |           |           |             |   |
| PM, n (%) | 15/24 (62.5) | 2/7 (28.6) | 0.198 | 16/28 (57.1) | 1/1 (100.0) | 0/2 (0) | 0.196 |
| ICD/AED, n (%) | 24/37 (64.9) | 12/15 (80.0) | 0.340 | 28/43 (65.1) | 2/3 (66.7) | 6/6 (100.0) | 0.214 |
| LCSD, n (%) | 4/37 (10.8) | 3/10 (30.0) | 0.155 | 5/42 (11.9) | 0/1 (0) | 2/4 (50.0) | 0.154 |
| **Outcome** |                                       |   |           |           |             |   |
| Death, n (%) | 17/52 (32.7) | 3/33 (9.1) | 0.017 | 19/59 (32.2) | 1/6 (16.7) | 0/20 (0) | 0.006 |
| Age at death, months [median (IQR)] | 2 (1.4–26) | 12 | 0.926 | 3 (1.1–29) | 1.5 (1.5–1.5) | 0.560 |
| Major adverse cardiac event (death/ACA/SCD/ICDD), n (%) | 37/52 (71.2) | 11/32 (34.4) | 0.001 | 40/58 (70.7) | 2/6 (33.3) | 6/20 (30.0) | 0.004 |
| Age at MACE, months [median (IQR)] | 24 (2–53) | 60 (20–147) | 0.156 | 27 (2–54) | 385 (2–768) | 138 (120–156) | 0.111 |

Statistically different differences are indicated in bold. ASD, autism spectrum disorder; PM, pacemaker; ICD, implantable automated defibrillator; AED, automatic external defibrillator; LCSD, left cervical sympathetic denervation; TS, Timothy syndrome; COTS, “cardiac only” Timothy syndrome; LQT8, isolated long QT syndrome, subtype 8.
between the index patient groups regarding disease and outcome parameters, remained statistically different, even at a higher significance level. Furthermore, the difference in age at death or at the time of MACE became statistically different, as patient with exon 8/8A mutations or patients with TS died at an earlier age and had MACE at an earlier age. Data are presented in Supplementary Table 1.

Discussion

In our systemic review we examined CACNA1C gene mutation associated Timothy syndrome, “cardiac only” Timothy syndrome, isolated long QT syndrome 8 and provided data that these disease forms exhibit major differences regarding clinical manifestations and outcome. These differences can be defined either based on the genotype or the phenotype.

In the literature, there is a high degree of controversy regarding the classification of Timothy syndrome. Since the original reports on TS1 and TS2, several proposals have been made to identify TS subtypes. One proposal suggested that all TS phenotypes resulting from mutations in CACNA1C should be classified as TS1, and when the next TS disease gene is discovered, it can be classified as TS2 (29). Another proposal recommended that TS1 and TS2 should include exclusively only patients with the p.Gly406Arg mutation in exon 8A (TS1) or in exon 8 (TS2), while the remaining alleles be called atypical TS (4). It has been also argued that there is no clinical utility to distinguishing TS1 from TS2 (30).

However, these proposals were based on small case series and mostly lacked evidence for the most profound question as to whether there is any major difference in the clinical manifestation or, more importantly, the outcome of TS subtypes. Here we provide data, that apart of syndactyly or baldness, there is no major differences regarding clinical manifestations or outcome measures between TS1 and TS2, either defining TS subtypes on the genotype or on the phenotype. Both subtypes are characterized by an extreme degree of QTc prolongation (median \( \geq 600 \text{ ms} \)) which is reflected in the similarly high MACE rate. All the above probably makes the distinction between TS1 and TS2 obsolete, at least with regard to clinical outcome, and may make the use of the descriptive terms “classical TS” (with syndactyly) and “non-classical TS” (without syndactyly) more appropriate, as it emphasizes that the two are similar diseases with comparable clinical outcomes.

On the other hand, there are important differences between TS, COTS and isolated LQT8. Based on the phenotype, Timothy syndrome is characterized by a much earlier disease onset, much more pronounced QTc prolongation and much higher mortality than “cardiac only” Timothy syndrome or isolated LQT8. Although phenotypic differences are the basis for the categorization of these disease forms, this is the first time that differences in ECG parameters or in the clinical outcome have been demonstrated. The degree of QTc prolongation is often extreme in TS (\( > 600 \text{ ms} \)), and it is \( > 500 \text{ ms} \) in \( > 90\% \) of TS patients, while it is only mildly prolonged (\( < 500 \text{ ms} \)) in COTS or LQTSs. This might be the primary reason for the higher rate of clinical complications, either death or MACE. Similar observations were made by Landstrom et al. based on 28 independent probands (26). Based on the above findings, the established categorization of these disease groups (TS, COTS and isolated LQT8) seems to be justified also on the grounds of clinical outcome.

Differences, like those outlined above, can be encountered if comparisons are made based on the genotype, i.e., between carriers of exon 8/8A mutations vs. non-exon 8/8A mutations. As exon 8/8A mutations are responsible for 83% of TS cases and only 17% of COTS and 10% of isolated LQT8, similar differences can be observed that was seen among TS, COTS and isolated LQT8. These include that disease onset is at much a younger age, phenotypic characteristics of TS are more prevalent, QTc prolongation is much more pronounced and clinical outcome is much more severe in patients with exon 8/8A mutations.

Additionally, the results of our systemic review demonstrated that TS is a rather homogenous disease genetically, as the p.Gly406Arg mutation either in exon 8 or exon 8A alone is responsible for 70% of the cases, and mutations affecting codons 402–407 is responsible for 85% of TS cases. The strongest relationship was seen between mutation p.Gly406Arg in exon 8A and “classical” TS, which is present in 93.5% of the patients. COTS and isolated LQT8 are more heterogenous in this regard having their causative mutations more scattered through the gene.

The cellular electrophysiological alterations caused by the different CACNA1C gene mutations alone are not sufficient to explain the above differences in phenotypic expression. CACNA1C mutations may result in channel dysfunction in different ways [recently reviewed in detail by Bauer et al. (4)], but the general mechanism is that these mutations lead to gain-of-function alleles of the gene, thereby prolonging the cardiac action potential (AP) and consequently the QT interval (10, 11, 15). The classical mechanism of channel dysfunction, demonstrated for TS mutations (exon 8A and p.Gly406Arg, and exon 8 p.Gly402Ser variants) in different expression systems, is a loss of voltage-dependent inactivation (VDI) of the channel, which leads to prolonged opening of the channel and subsequently causes an increase in the maximum flow of Ca\(^{2+} \) through the channel (peak current density) (10, 11, 15). Additional mechanisms, affecting calcium-dependent inactivation (CDI) (31, 32) and steady-state inactivation (SSI) of the channel, significantly increasing the window current, has also been demonstrated (in case of the p.Gly1911Arg mutation) (15). Alternative channel dysfunctional mechanisms are characterized by a reduction in
manifestations with much earlier disease onset, much more phenotypes. Timothy syndrome shows the most severe clinical manifestations and outcome. These differences can be defined either based on the genotype or on the phenotype. Among the syndromes 8 exhibit major differences regarding clinical involvement in the reported cases was not available. Although all efforts have been done to collect all the cases reported in the literature the study cohorts are still relatively small that limits our ability to draw definitive conclusions. Also, the timespan of the reports encompasses 15 years, from 2004 to 2019, which makes the comparison of individual reports difficult in terms of treatment and outcome over time.

Limitations

This systematic review harbors all the intrinsic shortcomings of a retrospective study. Given the retrospective nature of the study, clinical information on every aspect of multiorgan involvement in the reported cases was not available. Although all efforts have been done to collect all the cases reported in the literature the study cohorts are still relatively small that limits our ability to draw definitive conclusions. Also, the timespan of the reports encompasses 15 years, from 2004 to 2019, which makes the comparison of individual reports difficult in terms of treatment and outcome over time.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

All authors listed have made a substantial, direct, intellectual contribution to the work, and approved it for publication.

Funding

This study was supported by an Economic Development and Innovation Operative Program Grants (GINOP 2.3.2-15-2016-00048 and GINOP-2.3.3-15-2016-00039), by an Institutional Developments for Enhancing Intelligent Specialization Grant (EFOP-3.6.2-16-2017-00006) of the National Research, Development and Innovation Office and by the Research Fund of the Faculty Medicine, University of Szeged. RS was a recipient of the “Hetényi Géza” grant of the Faculty of Medicine, University of Szeged.

Conclusion

This current comprehensive systematic review demonstrates that CACNA1C gene mutation associated Timothy syndrome, “cardiac only” Timothy syndrome, and isolated long QT syndrome 8 exhibit major differences regarding clinical manifestations and outcome. These differences can be defined either based on the genotype or on the phenotype. Among the phenotypes Timothy syndrome shows the most severe clinical manifestations with much earlier disease onset, much more pronounced QTc prolongation and a much higher mortality than “cardiac only” Timothy syndrome or isolated LQT8. However, distinguishing TS subtypes, in any form, are not supported by our data.

Implications for practice include that a high degree of surveillance is warranted if these diseases, especially TS is identified because of the high rate of adverse cardiac events. Genotyping of the patients help to stratify the risk of the patients as exon 8/8A mutations carry higher risk.

Implications for research include the need for establishing a prospective world-wide registry to fully explore the phenotypic spectrum and clinical outcome of these diseases.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplemental material

The Supplemental Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.1021009/full#supplementary-material

References

1. Catterall WA, Goldin AL, Waxman SG. International union of pharmacology. XLVII. nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev. (2005) 57:397–409. doi: 10.1124/pr.57.4.4
2. Ertel EA, Campbell KP, Harpold MM, Hofmann F, Moti Y, Perez-Reyes E, et al. Nomenclature of voltage-gated calcium channels. Neuron. (2000) 25:533–5.
3. Soldatov NM. Genomic structure of human L-type Ca2+ channel. Genomics. (1994) 22:77–87.
4. Bauer R, Timothy KW, Golden A. Update on the molecular genetics of timothy syndrome. Front Pediatr. (2021) 9:668546. doi: 10.3389/fped.2021.668546
5. Boczek NJ, Ye D, Jin F, Tester DJ, Huseby A, Bos JM, et al. Identification and functional characterization of a novel CACNA1C-mediated cardiac disorder characterized by prolonged QT intervals with hypertrophic cardiomyopathy, congenital heart defects, and sudden cardiac death. Circ Arrhythmia Electrophysiol. (2015) 8:1122–32. doi: 10.1161/CIRC Arrhythmia Electrophysiol.310.002745
6. Wernhöner K, Friedrich C, Stallmeyer B, Coffey AJ, Grace A, Zumhagen S, et al. Gain-of-function mutations in the calcium channel CACNA1C (Cav1.2) cause non-syndromic long-QT but not Timothy syndrome. J Mol Cell Cardiol. (2015) 80:186–95. doi: 10.1016/j.yjmcc.2015.01.002
7. Fukuyama M, Wang Q, Kato K, Ohno S, Ding WG, Toyota F, et al. Long QT syndrome type-8: novel CACNA1C mutations causing QT prolongation and variant phenotypes. Europace. (2014) 16:1828–37.
8. Boczek NJ, Best JM, Tester DJ, Giudicessi JR, Middha S, Evans JM, et al. Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long QT syndrome. Circ Cardiovasc Genet. (2013) 6:279–89. doi: 10.1161/CIRCGENETICS.113.001318
9. Adler A, Novelli V, Amin AS, Abiusi E, Care M, Nannenberg EA, et al. An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome. Circulation. (2020) 141:418–28. doi: 10.1161/CIRCULATIONAHA.119.031132
10. Sławecki I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. (2004) 119:19–31. doi: 10.1016/j.cell.2004.09.011
11. Sławecki I, Timothy KW, Decher N, Kumar P, Sachse FR, Beggs AH, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA. (2005) 102:8089–96. doi: 10.1073/pnas.0502506102
12. Sepp R, Hateg L, Bacci A, Csokley J, Kornyei L, Borbas J, et al. Timothy syndrome 1 genotype without syndactyly and major extracardiac manifestations. Am J Med Genet Part A. (2017) 173:784–9. doi: 10.1002/ajmg.a.38084
13. Gillis J, Burzachek E, Antzelevitch C, Blaser S, Gross G, Turner L, et al. Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome. Am J Med Genet Part A. (2012) 158A:182–7. doi: 10.1002/ajmg.a.34355
14. Boczek NJ, Miller EM, Ye D, Nesterenko VV, Tester DJ, Antzelevitch C, et al. Novel Timothy syndrome mutation leading to increase in CACNA1C window current. Heart Rhythm. (2015) 12:211–9. doi: 10.1016/j.hrthm.2014.09.051
15. Hennessey JA, Boczek NJ, Jiang YH, Miller JD, Patrick W, Pfeiffer R, et al. A CACNA1C variant associated with reduced voltage-dependent inactivation, increased Cav1.2 channel window current, and arrhythmogenesis. PLoS One. (2014) 9:e106982. doi: 10.1371/journal.pone.0106982
16. Kosaki R, Ono H, Terasihma H, Kosaki K. Timothy syndrome-like condition with syndactyly but without prolongation of the QT interval. Am J Med Genet Part A. (2018) 176:1657–61. doi: 10.1002/ajmg.a.38083
17. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097
18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. (2015) 17:405–24.
19. Dufendach KA, Giudicessi JR, Boczek NJ, Ackerman MJ. Maternal mosaicism confounds the neonatal diagnosis of type 1 Timothy syndrome. Pediatrics. (2013) 131:e1991–5. doi: 10.1542/peds.2012-2941
20. Etheridge SP, Bowles NE, Arrington CB, Pilcher T, Rope A, Wilde AA, et al. Somatic mosaicism contributes to phenotypic variation in timothy syndrome. Am J Med Genet Part A. (2011) 155A:2578–83. doi: 10.1002/ajmg.a.34223
21. Baurand A, Falcon-Eischer S, Laurent G, Villain E, Bonnet C, Thauvin-Robinet C, et al. Incomplete timothy syndrome secondary to a mosaic mutation of the CACNA1C gene diagnosed using next-generation sequencing. Am J Med Genet Part A. (2017) 173:531–6. doi: 10.1002/ajmg.a.38045
22. Fröhler S, Küesch L, Mangnick C, Feldkamp M, Oppen-Rhein B, Berger F, et al. Exome sequencing helped the fine diagnosis of two siblings afflicted with atypical timothy syndrome (TS2). BMC Med Genet. (2014) 15:48. doi: 10.1186/1471-2350-15-48
23. Gao YF, Xue XL, Hu CY, Liu WL, Yuan Y, Sun HM, et al. Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome. Circ Arrhythmia Electrophysiol. (2013) 6:614–22. doi: 10.1161/CIRC ARL.113.000992
24. Kawaida M, Abe T, Nakanishi T, Miyahara Y, Yamagishi H, Sakamoto M, et al. A case of timothy syndrome with arterial medial dystrophy. Pathol Int. (2016) 66:587–92. doi: 10.1111/pin.12458
25. Krause U, Gravenhorst V, Kriebel T, Ruschewski W, Paul T. A rare association of long QT syndrome and syndactyly: timothy syndrome? (LQTS)? Clin Res Cardiol. (2010) 100:1123–7.
26. Landstrom AP, Boczek NJ, Ye D, Miyake CY, De la Utr CM, Allen HD. Novel long QT syndrome-associated missense mutation, L762F, in CACNA1C-encoded L-type calcium channel imparts a slower inactivation tau and increased sustained and window current. Int J Cardiol. (2016) 220:290–8. doi: 10.1016/j.ijcard.2016.08.081
27. Tunca Sahin, G, Ergül Y. A case report: mesilazine usage effective in the shortening of QTc interval and improving the T-wave alternans in timothy syndrome? Ann Noninvasive Electrocardiol. (2018) 23:e12522. doi: 10.1111/ane.12522
28. Hiippala A, Ojala T, Väisälä C, Happonen JM. 2:1 AV block due to extremely prolonged QT interval in newborns: variable genetic background. Cardiol Young. (2015) 25:S64.
29. Dufendach KA, Timothy K, Ackerman MJ, Blevins B, Pflaumer A, Etheridge S, et al. Clinical outcomes and modes of death in timothy syndrome: a multicenter international study of a rare disorder. JACC Clin Electrophysiol. (2018) 4:459–66. doi: 10.1016/j.jacep.2017.08.007

Frontiers in Cardiovascular Medicine 16 frontiersin.org
30. Diep V, Seaver LH. Long QT syndrome with craniofacial, digital, and neurologic features: is it useful to distinguish between timothy syndrome types 1 and 2? Am J Med Genet Part A. (2015) 167A:2780–5. doi: 10.1002/ajmg.a.37258
31. Barrett CE, Tsien RW. The Timothy syndrome mutation differentially affects voltage- and calcium-dependent inactivation of CaV1.2 L-type calcium channels. Proc Natl Acad Sci USA. (2008) 105:2157–62. doi: 10.1073/pnas.0710501105
32. Dick IE, Yoshi-Mukherjee R, Yang W, Yue DT. Arrhythmogenesis in timothy syndrome is associated with defects in Ca(2+)-dependent inactivation. Nat Commun. (2016) 7:10370. doi: 10.1038/ncomms10370
33. Kelu Bsbabi K, Zhao J, Mokrane AE, Segura E, Marsolais M, Gondin S, et al. Novel gain-of-function variant in CACNA1C associated with timothy syndrome, multiple accessory pathways, and noncompaction cardiomyopathy. Circ Genom Precis Med. (2020) 13:e003123. doi: 10.1161/CIRCGEN.120.003123
34. Otsuka J, Obno S, Saito H, Saitob A, Matsuura H, Horie M. A novel CACNA1C mutation identified in a patient with Timothy syndrome without syndactyly exerts both marked loss- and gain-of-function effects. Heart Rhythm Case Rep. (2018) 4:273–7. doi: 10.1016/j.hrcr.2018.03.003
35. Ye D, Tester DJ, Zhou W, Ackerman MJ. A novel pore region CACNA1C missense mutation identified in a patient with ventricular tachyarrhythmias in type calcium channel selectivity alteration. Circulation. (2017) 136:A15885.
36. Clark MB, Wrzesinski T, Garcia AB, Hall NAL, Kleinman JE, Hyde T, et al. Long-read sequencing reveals the complex splicing profile of the psychiatric risk gene CACNA1C in human brain. Mol Psychiatry. (2020) 25:37–47. doi: 10.1038/s41380-019-0583-1
37. Varro A, Bazcko I. Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol. (2011) 164:14–36. doi: 10.1111/j.1365-3104.2011.04581.x
38. Lo-A-Njoe SM, Wilde AA, van Erven I, Blom NA. Syndactyly and long QT syndrome (CaV1.2 missense mutation G406R) is associated with hypertrophic cardiomyopathy. Heart Rhythm. (2005) 2:1365–8. doi: 10.1016/j.hrthm.2005.08.024
39. Jacobs A, Knight BP, McDonald KT, Burke MC. Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8). Heart Rhythm. (2006) 3:967–70. doi: 10.1016/j.hrthm.2006.04.024
40. An HS, Choi EY, Kwon BS, Kim GB, Rae EJ, Noh CI, et al. Sudden cardiac arrest during anaesthesia in a 30-month-old boy with syndactyly: a case of genetically proven Timothy syndrome. J Korean Med Sci. (2013) 28:788–91. doi: 10.3346/jkms.2013.28.5.788
41. Corona-Rivera JR, Barrios-Prieto E, Nieto-Garcia R, Blosse R, Priori S, Napolitano C, et al. Unusual retrospective prenatal findings in a male newborn with timothy syndrome type 1. Eur J Med Genet. (2011) 54:332–5. doi: 10.1016/j.ejmg.2015.04.001
42. Ergül Y, Ozyilmaz I, Haydin S, Gazelas A, Tuzcu V. A rare association with suffered cardiac arrest, long QT interval, and syndactyly: timothy syndrome (LQT-8). Anatol J Cardiol. (2015) 15:672–4. doi: 10.5152/AnatolJCardiol.2015.6315
43. Hiippala A, Tallila I, Mäldykangas S, Koskenvuo JW, Ala-latalo TP. Expanding the phenotype of timothy syndrome type 2: an adolescent with ventricular fibrillation but normal development. Am J Med Genet Part A. (2015) 167A:629–34. doi: 10.1002/ajmg.a.36924
44. Gunay EE, Turkgenc B, Valug K, Çetiner N, Cevik SB, Yakciz C, et al. A unique case of timothy syndrome due to coexistence of CACNA1C and Ank2 mutations. Cardio Young. (2016) 26:572–3.
45. Philipp I, Rodriguez FH. Cardiac arrest refractory to standard intervention in atypical timothy syndrome (LQT8 type 2). Proceedings. (2016) 29:160–2. doi: 10.1080/08998280.2016.1192938
46. Gardner RJM, Crozier IG, Binfield AL, Love DR, Lehnert K, Gibson K, et al. Penetration and expressivity of the R458H CACNA1C variant in a five-generation pedigree segregating an arrhythmogenic channelopathy. Mol Genet Genomic Med. (2019) 7:e00476. doi: 10.1002/mgg3.476
47. Kojima A, Shukata I, Okamura T, Higaki T, Ohto S, Horie M, et al. Refractory ventricular fibrillations after surgical repair of atrial septal defects in a patient with CACNA1C gene mutation - case report. J Cardiothorac Surg. (2017) 12.118. doi: 10.1186/s13019-017-0683-4
48. Seo SH, Kim SY, Cho SI, Park H, Lee S, Choi JM, et al. Application of multigene panel sequencing in patients with prolonged rate-corrected QT interval and no pathogenic variants detected in KCNQ1, KCNH2, and SCN5A. Ann Lab Med. (2018) 38:54–8. doi: 10.3343/alm.2018.38.1.54
49. Walsh MA, Turner C, Timothy KW, Seller N, Hares DL, James AF, et al. A multicentre study of patients with timothy syndrome. Europace. (2018) 20:377–85.
50. Colson C, Mitter H, Busson A, Leenhardt A, Denjoy I, Fressard V, et al. Unusual clinical description of adult with timothy syndrome, carrier of a new heterozygote mutation of CACNA1C. Eur J Med Genet. (2019) 62:103648. doi: 10.1016/j.ejmg.2019.04.005